inviCRO specializes in advanced imaging solutions and analytics for drug discovery and development, particularly in the fields of oncology and central nervous system (CNS) research. Their offerings include a comprehensive range of imaging modalities such as PET, SPECT, and MRI, which are utilized for both preclinical and clinical studies. The company has managed over 3,500 research trials and processed more than 40 million DICOM images, showcasing their extensive experience in executing complex imaging studies across various therapeutic areas. Their capabilities extend to the development of radiopharmaceuticals, including PSMA-PET solutions for prostate cancer, where they provide end-to-end support from radiochemistry development to clinical trial management.

In addition to their imaging services, inviCRO employs advanced analytics through their IQ Analytics Platform, which integrates artificial intelligence to enhance image analysis and quantification. This platform allows for automated segmentation and detailed assessment of imaging data, facilitating more efficient and accurate decision-making in drug development. Their expertise in coordinating multi-center studies and managing radiotracer supply further underscores their commitment to providing comprehensive support throughout all phases of drug discovery and development. With a focus on delivering meaningful insights and data-driven results, inviCRO positions itself as a leader in the imaging CRO space.

United States

Invicro is a company in the medical imaging and biotechnology industry that specializes in imaging services for pharmaceutical and life sciences companies.

inviCRO

Company Details